Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes

scientific article published on 11 November 2019

Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.VACCINE.2019.10.073
P932PMC publication ID6980772
P698PubMed publication ID31727504

P50authorMelanie K B WillsQ84964706
P2093author name stringIain L Mainprize
Jonathan F Lovell
Yi-Pin Lin
Wei-Chiao Huang
Jasmin Federizon
Xuedan He
Thomas M Hart
Christopher Beltran
Amber Frye
Ashley L Marcinkiewicz
P2860cites workThe Lyme vaccine: a cautionary taleQ22251377
Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptideQ24630127
Vaccine Adjuvants: from 1920 to 2015 and BeyondQ26783879
Structural identification of a key protective B-cell epitope in Lyme disease antigen OspAQ27629686
TROSPA, an Ixodes scapularis receptor for Borrelia burgdorferiQ28292578
Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) miceQ33584120
Clonal polymorphism of Borrelia burgdorferi strain B31 MI: implications for mutagenesis in an infectious strain backgroundQ34120882
Enhancement of immune response towards non-lipidized Borrelia burgdorferi recombinant OspC antigen by binding onto the surface of metallochelating nanoliposomes with entrapped lipophilic derivatives of norAbuMDP.Q34183802
Mechanism of action of cytochalasin B on actinQ34272923
Design and development of a novel vaccine for protection against Lyme borreliosisQ34542417
Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens.Q35535265
The Position of His-Tag in Recombinant OspC and Application of Various Adjuvants Affects the Intensity and Quality of Specific Antibody Response after Immunization of Experimental MiceQ35915376
An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitopeQ36017879
Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccineQ36366055
Liposomes as carriers of antigens and adjuvantsQ36660595
Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized miceQ37058962
Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme diseaseQ37099227
Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigensQ37191759
The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypesQ38597818
SplitCore: an exceptionally versatile viral nanoparticle for native whole protein display regardless of 3D structureQ39118758
Infection Rate by Trypanosoma cruzi and Biased Vertebrate Host Selection in the Triatoma dimidiata (Hemiptera: Reduvidae) Species ComplexQ39381514
Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: Implications for vaccine developmentQ40223320
Characterization and optimization of a novel vaccine for protection against Lyme borreliosisQ40305701
NMR identification of epitopes of Lyme disease antigen OspA to monoclonal antibodies.Q47781258
Identification of Lyme borreliae proteins promoting vertebrate host blood-specific spirochete survival in Ixodes scapularis nymphs using artificial feeding chambers.Q52322007
An in vitro feeding assay to test acaricides for control of hard ticks.Q52673982
A silicone membrane for in vitro feeding of Ixodes scapularis (Ixodida: Ixodidae).Q53763278
Outer surface protein A (OspA) from the Lyme disease spirochete, Borrelia burgdorferi: high level expression and purification of a soluble recombinant form of OspA.Q54312791
Lyme borreliosisQ56764150
Correlates of adjuvanticity: A review on adjuvants in licensed vaccinesQ57094639
Structure-based Design of a Second-generation Lyme Disease Vaccine Based on a C-terminal Fragment of Borrelia burgdorferi OspAQ57266635
A malaria vaccine adjuvant based on recombinant antigen binding to liposomesQ57295566
The Spirochetal Etiology of Lyme DiseaseQ58402764
Structural analysis of an outer surface protein from the Lyme disease spirochete, Borrelia burgdorferi, using circular dichroism and fluorescence spectroscopyQ68083619
Lipoproteins from Borrelia burgdorferi applied in liposomes and presented by dendritic cells induce CD8(+) T-lymphocytes in vitroQ73834081
Blood treatment of Lyme borreliae demonstrates the mechanism of CspZ-mediated complement evasion to promote systemic infection in vertebrate hostsQ90670739
Antigen Engineering Approaches for Lyme Disease VaccinesQ93105912
"Ticking Bomb": The Impact of Climate Change on the Incidence of Lyme DiseaseQ93354155
P433issue4
P921main subjectLyme diseaseQ201989
P304page(s)942-950
P577publication date2019-11-11
P1433published inVaccineQ7907941
P1476titleImmunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes
P478volume38

Reverse relations

Q90699157Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragmentcites workP2860

Search more.